FDA Expands Approval for Enhertu®
On May 5, 2022, the FDA expanded approval for trastuzumab deruxtecan (Enhertu®, AstraZeneca and Daiichi Sankyo) for the treatment of patients with HER2-positive...
Read More PAST ARTICLES
2021
- Metastatic Breast Cancer News from 2021 ESMO
- Metastatic Breast Cancer News from ASCO 2021
- MBC News from 2021 AACR Meeting
- St. Gallen International Breast Cancer Conference 2021
- 2021 Miami Breast Cancer Conference
- FDA Approves MARGENZA
- What is Next-Generation Sequencing?
- Lines of Therapy: New Drugs May Change MBC Treatment
2020
SEARCH OUR SITE
for past articles or specific information.